Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...
Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
Bristol Myers’s stock pops as earnings top estimates and company raises guidance
Princeton, N.J.-based Bristol Myers BMY had net income of $1.2 billion, or 60 cents a share, in the quarter, down from $1.9 ...
The Associated Press on MSN4d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...
Bristol-Myers raises outlook ahead of consensus after Q3 beat
Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...
FiercePharma5d
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency'
Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Bristol-Myers Squibb Co. (NYSE: BMY) is an American multinational pharmaceutical company that discovers, develops, and ...
MarketWatch13d
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY advanced 1.23% to $52.76 Tuesday, on what proved to be an all-around poor trading ...
Bristol Myers presents new long-term data from EMERGENT study of COBENFY
Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...
Morningstar1d
Bristol-Myers Squibb Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...